Shares of Co-Diagnostics are stabilizing at $8.73 in pre-market Monday, up 2.3%, as the micro-cap diagnostics maker tries to find a floor after one of 2026's most violent round trips. The stock surged more than 630% over six sessions as investors rushed into diagnostics plays amid growing concerns over the Ebola outbreak spreading across the DRC and Uganda. It then shed roughly 24% in a single day on May 29, falling from $11.19 to $8.53 on what appears to be textbook profit-taking. No new company news has surfaced since.
A Real Outbreak, But No Product to Sell Yet The catalyst was genuine: the WHO reported more than 900 suspected Ebola cases and 220 suspected deaths, with the epidemic "currently outpacing response operations." Co-Diagnostics announced it was developing a PCR test for the Bundibugyo strain behind the outbreak. But its testing platform and all associated tests remain subject to FDA and regulatory review and are not yet available for sale. Investors are pricing in a product that doesn't exist commercially.
The Numbers Behind the Hype Are Paper-Thin
Co-Diagnostics reported first-quarter product revenue of just $145,954, a net loss of $9.14 million, and cash of $8.23 million at March 31.
With CODX's small market capitalization and historically high volatility, the rally may have been amplified by momentum trading and short covering.
A 1-for-30 reverse stock split executed in January 2026 to regain Nasdaq compliance tightened the available shares , making each burst of buying disproportionately powerful.
A $150 Million Shelf Filing Looms Over Shareholders
An S-3 shelf filed on May 12 allows CODX to issue up to $150 million in various securities for working capital and general corporate purposes. For a company burning roughly $9 million per quarter, that shelf is a lifeline — and a dilution risk. A separate $3 million private placement on May 21 already priced warrants at just $1.571 per share , well below today's price, meaning those holders can buy cheap stock and sell into strength.
Institutional Money Was Already Heading for the Exit
Renaissance Technologies, Geode Capital, and BlackRock all liquidated their entire CODX positions in Q1 2026 , before the Ebola rally even began. Short interest sat below 1% of the float before the surge , confirming this was a retail-driven trade, not an institutional conviction bet. The question now: will the Ebola crisis deepen enough to turn a headline into a revenue stream — or will shareholders be left holding a stock that ran on fear alone?